INOVAÇÃO NOS BIOMARCADORES DA DOENÇA DE ALZHEIMER

Alzheimer's Disease (AD) has been growing alarmingly on the global health scene, being the main cause of dementia in the elderly and affecting millions of people around the world. The socioeconomic impact of AD is significant, with high costs for health systems and families, as well as deterioration of the patient's memory and autonomy. Currently, the diagnosis of AD is based on clinical criteria and biomarkers, which is essential to improve early diagnosis and initiation of therapy. Therefore, this study was carried out with the general objective of pointing out innovations in the biomarkers used to detect Alzheimer's disease. The research methodology is bibliographic, in terms of objectives, exploratory-descriptive and in terms of the cause and effect relationships of phenomena, it is explanatory, qualitative in nature, using a review of bibliographic literature, where articles indexed in scientific journals published in SciELO were consulted. (medical publications, Ministry of Health, National Cancer Institute, among others). Publications were selected with an emphasis on the years 2019 to 2023.